Dr. Karnovsky's research interests involve the analysis of high throughout omics data, focusing primarily on metabolomics, and the development of computational methods and tools for the analysis and integration of metabolomics data with other types of genomic data. She is also interested in biomedical ontologies and one of her current projects involves the development of Informed Consent Ontology.
Dr. Karnovsky's background includes Ph.D. in cell and developmental biology (Russian Academy of Sciences), postdoctoral work at the University of Colorado at Boulder and nine years of bioinformatics work in Pharmaceutical industry (at Pharmacia and at Pfizer). She has broad experience in identification and validation of therapeutic targets in variety of disease areas including antibacterials, CNS and dermatology. Dr. Karnovsky is also interested in structural aspects of drug/target interactions and the integration of chemical and genomic domains.
Dr. Karnovsky is a Research Assistant Professor of Computational Medicine and Bioinformatics and her research program has a special interest in developing bioinformatics tools for integration of multiscalar data, including metabolomics, working closely with NCIBI. Her group developed a unique tool Metscape, a Cytoscape plug-in designed to visualize metabolites and associated pathways. Dr. Karnovsky works with users to select the proper bioinformatics tools to use for their metabolic analysis and continue the expansion of the numbers of compounds and pathways contained in Metab2Mesh and Metscape. She also leads the development of novel bioinformatics algorithms through which unknown compounds can be identified.
Along with Ms. Ridenour, Dr. Karnovsky administers the Pilot/Feasibility Program. She operates with advice, assistance, and oversight from the Executive Committee, which is responsible for the review and selection of pilot projects.